Prospector
Profile
07.1413
|
| |
| Baywood International, Inc. |
NAICS |
541710 |
| 14950 North 83rd Place, Suite 1
Scottsdale, AZ 85260 |
Description |
Biotechnology |
| (480) 951-3956 |
Employees |
9 |
| http://www.bywd.com/ |
Revenue |
(mil) |
1.0780 |
| |
Income |
(mil) |
-0.6250 |
| |
Assets |
(mil) |
0.4800 |
| |
Liability |
(mil) |
3.2350 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Default
|
| |
|
Event:
Baywood International, Inc. discloses that it is in default on scheduled debt repayments of $799,945 for notes payable as of June 30, 2007. The creditors have not amended the notes nor have they demanded payment or accrual of interest.
|
| |
|
Intellectual Property:
The Company registers its principal brand names in the United States and certain foreign countries. The material trademarks include the Baywood PURECHOICE®, Baywood SOLUTIONS® and Complete La Femme® and LifeTime® brands. The Company currently owns these brand names as registered trademarks and substantially all of its net sales were from products bearing these brands. Additionally, the Company licenses directly or indirectly through contract manufacturers certain intellectual property from third parties. An example is Phase 2™, which is the primary ingredient in its Carb Eliminator™ and Maximum Strength Carb Eliminator™ and is the trademark of Pharmachem Labs. The Company is required to pay a royalty per unit to the owner of the patent under which it sells two products, Baywood Original Snore Formula™ and Baywood Original Allergy Formula™. [SEC Filing SB-2 07-23-07]
|
| |
|
Description:
The Company engages in the development, production, marketing, and distribution of nutraceutical products and other novel technologies for therapeutic applications.
|
| |
|
Officers:
Neil Reithinger (Chair, Pres. & CEO); Karl H. Rullich (VP, Sec. & Dir.); Thomas Pinkowski (VP); O. Lee Tawes, III (Dir.); David Tsiang (Dir.); Neil Russell (Dir.)
|
| |
|
Auditor:
Epstein Weber & Conover PLC
|
| |
|
Securities:
Common Stock-Symbol BYWD.OB; OTC BB;
131,596,110 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
